Regeneron Executive and Leadership Team

November, 2026

Leadership Overview

Regeneron has 5 executives leading key functions including corporate strategy, human resources, regulatory compliance, clinical development, and scientific innovation.

Driven by a commitment to advanced biotechnology, Regeneron delivers life-changing medicines for serious diseases through proprietary science and rigorous research, aiming to transform patient outcomes globally.

Leadership Roles at Regeneron

  • Co-Chair, President & Chief Executive Officer - Leonard Schleifer
  • President & Scientific Office Chief & Co-Founder - George Yancopoulos
  • Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources - Erin Rohr
  • Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality - Kim Brenner
  • Genetic Medicines Clinical Development Unit Chief of Staff - Michelle DeSimone
  • Leonard Schleifer - Co-Chair, President & Chief Executive Officer

    Leonard Schleifer, the Co-Chair, President & Chief Executive Officer at Regeneron, directs the overarching corporate strategy and long-term vision for the biotechnology enterprise. Overseeing the discovery and commercialization of innovative medicines, the Chief Executive Officer ensures alignment between scientific research and market needs for serious diseases. This leadership role involves managing complex stakeholder relationships and driving growth across North American and international markets. By prioritizing advanced science, Leonard Schleifer maintains the company's competitive edge in the pharmaceutical sector. Schleifer fosters a culture of innovation that supports the development of treatments for cancer, eye diseases, and inflammatory disorders. Through consistent focus on operational excellence, the Chief Executive Officer secures the financial stability required to sustain high-impact research initiatives. Ultimately, Schleifer guides the organization toward achieving significant breakthroughs in patient care while navigating the evolving regulatory landscape of the global biotechnology industry.
    Leonard Schleifer

    George Yancopoulos - President & Scientific Office Chief & Co-Founder

    George Yancopoulos, the President & Scientific Office Chief & Co-Founder at Regeneron, directs the core scientific research and discovery engine that defines the company's biotechnology portfolio. Overseeing the development of proprietary technologies, the Scientific Office Chief ensures that the organization remains at the forefront of innovation for cancer and rare disease treatments. This leadership role involves guiding the research strategy and fostering a culture of scientific excellence that drives the creation of life-changing medicines. By championing advanced research methodologies, George Yancopoulos maintains the company's position as a pioneer in the pharmaceutical industry. Yancopoulos collaborates with internal teams to translate complex biological insights into viable therapeutic candidates. Through the oversight of the scientific pipeline, the President ensures that the company's research efforts align with the most pressing unmet medical needs. Ultimately, Yancopoulos secures the long-term scientific viability and competitive advantage of the entire organization.

    Erin Rohr - Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources

    Erin Rohr, the Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources at Regeneron, architects the talent acquisition and organizational development frameworks necessary for a high-growth biotechnology firm. Overseeing human capital initiatives, the Vice President ensures that the workforce remains aligned with the company's mission to discover and commercialize life-changing treatments. This leadership role involves designing performance management systems and fostering an inclusive culture that attracts top-tier scientific talent. By optimizing internal processes, Erin Rohr directly impacts the efficiency of cross-functional teams working on rare disease research. Rohr manages the integration of human resources strategies with broader corporate objectives to support global operations. Through the implementation of robust training programs, the Vice President strengthens the internal capabilities required to sustain long-term innovation. Ultimately, Rohr drives the organizational health and employee engagement levels essential for maintaining the company's status as a leader in pharmaceutical manufacturing.

    Kim Brenner - Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality

    Kim Brenner, the Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality at Regeneron, directs the critical infrastructure governing regulatory compliance and product safety standards. Overseeing the quality assurance frameworks, the Executive VP ensures that all clinical development processes meet rigorous international benchmarks for patient safety. This leadership role involves managing complex interactions with global health authorities to facilitate the approval of innovative medicines. By streamlining operational workflows, Kim Brenner enhances the speed and reliability of the drug development pipeline. Brenner coordinates with scientific teams to maintain the highest standards of integrity across all manufacturing stages. Through the implementation of advanced quality control systems, the Executive VP mitigates risks associated with the commercialization of treatments for inflammatory disorders and rare diseases. Ultimately, Brenner secures the operational foundation necessary for the company to deliver safe, effective therapies to patients worldwide.

    Michelle DeSimone - Genetic Medicines Clinical Development Unit Chief of Staff

    Michelle DeSimone, the Genetic Medicines Clinical Development Unit Chief of Staff at Regeneron, executes the operational strategy for the clinical advancement of next-generation genetic therapies. Overseeing the coordination between research units and clinical trial sites, the Chief of Staff ensures that development timelines remain on track for complex therapeutic programs. This leadership role involves managing resource allocation and cross-functional communication to accelerate the transition from laboratory discovery to patient-focused clinical trials. By optimizing the execution of clinical protocols, Michelle DeSimone directly supports the company's mission to address serious diseases through advanced science. DeSimone facilitates the alignment of clinical objectives with broader corporate goals, ensuring that genetic medicine initiatives receive the necessary support for success. Through the management of internal project workflows, the Chief of Staff enhances the efficiency of the development pipeline. Ultimately, DeSimone drives the operational progress required to bring life-changing genetic treatments to market.

    Explore Leadership Teams in Manufacturing

    Frequently Asked Questions Regarding Regeneron Top Executives and Leadership Team

    Who leads Regeneron?
    Regeneron is led by Leonard Schleifer (Co-Chair, President & Chief Executive Officer), along with executives such as George Yancopoulos (President & Scientific Office Chief & Co-Founder) and Erin Rohr (Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources).
    Who is part of Regeneron’s executive team?
    The executive team of Regeneron includes leaders such as Leonard Schleifer (Co-Chair, President & Chief Executive Officer), George Yancopoulos (President & Scientific Office Chief & Co-Founder), Erin Rohr (Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources) and other senior executives.
    How many executives does Regeneron have?
    Regeneron has 5 executives leading key business areas.
    What roles are included in Regeneron’s leadership team?
    The leadership team of Regeneron includes roles such as Co-Chair, President & Chief Executive Officer, President & Scientific Office Chief & Co-Founder, Strategic HR Business Partner & To Chief of Staff & Vice President, Human Resources, Head Operations Strategy, To Chief of Staff & Executive VP, Regulatory, Patient Safety & Quality, Genetic Medicines Clinical Development Unit Chief of Staff.